Find and Pitch Jounalists, Get Your Story Covered

Tags: osimertinib amivantamab egfr inhibitor lung cancer liquid

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	EC approves Rybrevant with Lazcluze for advanced lung cancer - 20 days ago Everest therapy shows promise in nephropathy trial - about 2 months ago MHRA grants approval for bladder cancer drug erdafitinib - 3 months ago Amgen’s trial brings new hope for IgG4-RD patients - 8 months ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more - about 1 month ago STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit - over 1 year ago
3	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia - about 1 month ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 11 months ago New Oral Drug Approved for Metastatic Colorectal Cancer - about 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - about 1 year ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - about 1 year ago
4	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 2 months ago Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - 3 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 10 months ago
5	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	FDA Panel Rejects SGLT1/2 Inhibitor for Type 1 Diabetes - 3 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 4 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 5 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - about 1 year ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - about 1 year ago Novel Drug Makes Its Case for Pretreated Primary Biliary Cholangitis - about 1 year ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago
6	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 3 months ago Interim ALIGN Data: Atrasentan Cuts Proteinuria in IgA Nephropathy - 3 months ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - 3 months ago Once-Rejected Drug Now FDA Approved for CKD-Related Anemia - 10 months ago One Class of Antidiabetic Linked With Lower Kidney Stone Risk - 12 months ago In Acute Kidney Disease, SGLT2 inhibitors Were All-Around Protective - about 1 year ago Quick Albuminuria Reduction Key Factor in Finerenone's Efficacy - about 1 year ago Kidney Week Roundup: Cell Therapy Cuts Immunosuppressive Drug Use Post-Transplant - about 1 year ago Sparsentan Bests Irbesartan for Preserving Kidney Function in IgA Nephropathy - about 1 year ago Sparsentan Failed to Preserve Kidney Function Over Time in FSGS - about 1 year ago FDA Approves First Phosphate Absorption Inhibitor for CKD - over 1 year ago FDA Approves Another SGLT2 Inhibitor for Treating CKD - over 1 year ago
7	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 4 months ago FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 5 months ago FDA Grants Accelerated Approval for Elafibranor as Treatment of Primary Biliary Cholangitis - 7 months ago FDA Approves Sotatercept-csrk for Pulmonary Arterial Hypertension - 10 months ago FDA Grants Orphan Drug Designation to Felzartamab for Kidney Transplant Recipients - 10 months ago FLOW Trial Results Demonstrate Positive Kidney Outcomes With Semaglutide - 11 months ago FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC - 11 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - about 1 year ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - about 1 year ago FDA Grants Breakthrough Therapy Designation to Novel Drug for Progressive Pulmonary Fibrosis - about 1 year ago FDA Approves Empagliflozin for Adults With Chronic Kidney Disease at Risk of Progression - over 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago
8	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 5 months ago
9	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure - 10 months ago Study: Empagliflozin Reduces MACE Regardless of Baseline Albuminuria Levels - 10 months ago
10	Tara Haelle MedPage Today Sci/health journalist. Feminist. Educator. Photographer. Author. DFW science journalismhealthphotographyteaching	SGLT2 Inhibitors Tied to Better NAFLD Outcomes vs Other Antidiabetic Agents - 11 months ago

Journalists covering egfr inhibitor